Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 7/20 | 0.50 |
| ▸ | MMP13 | P45452 | 5/20 | 0.50 |
| ▸ | MMP14 | P50281 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP3 | P08254 | 2/20 | 0.50 |
| ▸ | MMP7 | P09237 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | MMP10 | P09238 | 1/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.50 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7305973 | 0.88 | MEN1 (0.43) | MMP1MMP13MMP14MMP2MMP3 | |
| SCHEMBL7303606 | 0.88 | MMP1 (0.43) | MMP1MMP13MMP14MMP2MMP3 | |
| SCHEMBL7308927 | 0.87 | MMP1 (0.50) | MMP1MMP13MMP14MMP2MMP3 | |
| SCHEMBL7304591 | 0.87 | MMP1 (0.64) | MMP1MMP13MMP14MMP2MMP3 | |
| SCHEMBL7302178 | 0.85 | MMP1 (0.46) | MMP1MMP13MMP14MMP2MMP3 | |
| SCHEMBL4640306 | 0.82 | MMP1 (0.43) | MMP1MMP13MMP14MMP2MMP3 | |
| SCHEMBL6995857 | 0.80 | MMP1 (0.46) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7313882 | 0.78 | MMP1 (0.55) | MMP1MMP13MMP14MMP2MMP3 | |
| SCHEMBL7302297 | 0.77 | MEN1 (0.44) | MMP13ADAM17ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL9938067 | 0.77 | MMP1 (0.77) | MMP1MMP13MMP14MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012080050-A1 | SOLID FORMS OF A PHENOXYBENZENESULFONYL COMPOUND | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| EP-2144604-B1 | Methods for the treatment of chronic viral hepatitis C using RO 113-0830 | CONATUS PHARMACEUTICALS INC (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20110212056-A1 | COMBINATION THERAPY FOR THE TREATMENT OF LIVER DISEASES | CONATUS PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| EP-2144604-A2 | METHODS FOR THE TREATMENT OF LIVER DISEASES USING SPECIFIED MATRIX METALLOPROTEINASE (MMP) INHIBITORS | Conatus Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008106166-A2 | METHODS FOR THE TREATMENT OF LIVER DISEASES USING SPECIFIED MATRIX METALLOPROTEINASE (MMP) INHIBITORS | CONATUS PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106167-A1 | COMBINATION THERAPY COMPRISING MATRIX METALLOPROTEINASE INHIBITORS AND CASPASE INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | CONATUS PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207569-A1 | Methods for the treatment of liver diseases | CONATUS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207605-A1 | Combination therapy for the treatment of liver diseases | CONATUS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| CN-1388117-A | Process for prodcing 3-aryl sulfate iso-hydroximic acid | HOFFMANN LA ROCHE (CH) | 2003-01-01 | — | — | CN | disclosed |
| EP-0780386-B1 | Matrix metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2002-10-02 | — | — | EP | disclosed |
| CN-1240208-A | Process for preparing 3-arylsulfur hydroxamic acids | HOFFMANN LA ROCHE (CH) | 2000-01-05 | — | — | CN | disclosed |
| EP-0780386-A1 | Matrix metalloprotease inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212056-A1 | COMBINATION THERAPY FOR THE TREATMENT OF LIVER DISEASES | MMP10, MMP3, GOT2 | MMP1 16/4885MMP13 25/4885MMP14 28/4885 |
| US-20080207605-A1 | Combination therapy for the treatment of liver diseases | MMP10, MMP3, GOT2 | MMP1 16/4885MMP13 25/4885MMP14 28/4885 |
| US-20080207569-A1 | Methods for the treatment of liver diseases | MMP1, PYGL, MMP8 | MMP1 1/4885MMP13 14/4885MMP14 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.